We concluded that administration of rMOv18 IgE to tumour‐bearing rats induced no clinical, histopathological or metabolic signs of a type I hypersensitivity reaction, even at weekly 50 mg/kg doses. The gene discussed is IGHE; the disease is neoplasm.